open access

Vol 82, No 3 (2014)
REVIEWS
Submitted: 2014-04-30
Accepted: 2014-04-30
Get Citation

Current methods to detect EGFR gene mutations as predictive factor for targeted therapies in non-small cell lung cancer — is there a „golden standard” in diagnostics?

Michał Skroński, Adam Szpechciński, Joanna Chorostowska- Wynimko
DOI: 10.5603/PiAP.2014.0036
·
Pneumonol Alergol Pol 2014;82(3):311-322.

open access

Vol 82, No 3 (2014)
REVIEWS
Submitted: 2014-04-30
Accepted: 2014-04-30

Abstract

According to current Polish and international recommendations, detection of EGFR gene somatic mutations is the essential part of routine diagnostic algorithm in advanced NSCLC patients considered for tyrosine kinase inhibitor therapy. Molecular heterogeneity of tumor tissue and cytology materials used for molecular diagnostics is challenging for classic methods of genetic analysis, such as Sanger sequencing, driving the development and implementation of specialized, highly sensitive techniques for mutations detection. Constant, dynamic progress in molecular biology techniques, particularly development of next-generation sequencing, should enable clinical implementation of simultaneous multiple therapeutic biomarkers analysis as well as non-invasive EGFR mutations diagnostic based on free-circulating DNA isolated from blood of non-small cell lung cancer patients.

Abstract

According to current Polish and international recommendations, detection of EGFR gene somatic mutations is the essential part of routine diagnostic algorithm in advanced NSCLC patients considered for tyrosine kinase inhibitor therapy. Molecular heterogeneity of tumor tissue and cytology materials used for molecular diagnostics is challenging for classic methods of genetic analysis, such as Sanger sequencing, driving the development and implementation of specialized, highly sensitive techniques for mutations detection. Constant, dynamic progress in molecular biology techniques, particularly development of next-generation sequencing, should enable clinical implementation of simultaneous multiple therapeutic biomarkers analysis as well as non-invasive EGFR mutations diagnostic based on free-circulating DNA isolated from blood of non-small cell lung cancer patients.

Get Citation

Keywords

EGFR mutations, molecular diagnostics, lung cancer, diagnostic methodsEGFR mutations, molecular diagEGFR mutations, molecular diagnostics, lung cancer, diagnostic methods

About this article
Title

Current methods to detect EGFR gene mutations as predictive factor for targeted therapies in non-small cell lung cancer — is there a „golden standard” in diagnostics?

Journal

Advances in Respiratory Medicine

Issue

Vol 82, No 3 (2014)

Pages

311-322

DOI

10.5603/PiAP.2014.0036

Bibliographic record

Pneumonol Alergol Pol 2014;82(3):311-322.

Keywords

EGFR mutations
molecular diagnostics
lung cancer
diagnostic methodsEGFR mutations
molecular diagEGFR mutations
molecular diagnostics
lung cancer
diagnostic methods

Authors

Michał Skroński
Adam Szpechciński
Joanna Chorostowska- Wynimko

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl